BioPharma Dive reports the FDA approved Scholar Rock's Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug blocks myostatin, a protein that limits muscle growth, and is cleared for patients 2 and older alongside existing SMN2-targeted therapies. It is the first SMA therapy aimed directly at muscle loss rather than the underlying genetic mechanism.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.